Replies to post #799502 on NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

NWBO bought Advent for a very reasonable sum. Then you started dissing Advent as worthless.

Nope. I asserted the book value is either negligible or negative. We will see come next year if I am right. Either way. if you cannot understand the difference between book value and "value", that is on you

Ashkan was right about JAMA timing, but you weren’t.

As far as Ashkan, I have no idea exactly what you are talking about. But I would expect an author of a paper would likely know about when it was to be published. And I do not recall making any statements about when a paper would published. I admit I thought the paper would need to do a better job of explaining the trial than NYAS did if it was to be published in a major journal. Shame on JAMA IMO.

You thought the MAA was going to rejection/appeal in April. As of November 20, it was still under review and LP decided to announce beginning construction on a C suite in order to double her current capacity which means she’s planning on a transition to Eden for further scale up.

I am still virtually certain the MHRA has major objections. As far as LP building MFG, that is what she does. Means nothing for DC-L.

BTW, did you not bet me wrt MHRA approval by Feb(?) 2025? Terms were an admission you were wrong. Just like you were wrong in calling me an idiot for thinking no approval in 2024. Crickets.